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Introduction
Infections of the central nervous system include meningitis
(inﬂammation of the cerebral or spinal meninges),
encephalitis (manifestations of cerebral symptoms due to
bacterial and viral invasion of the central nervous system),
abscess and parasitic infections. Infections other than
meningitis frequently show clinical features, such as pyr-
exia, headache, nausea/vomiting, nuchal rigidity, etc.,
similar to those of meningitis, since the infections develop
at sites adjacent to the meninges.
The infections of the central nervous system may be
caused by many types of pathogenic microorganisms
including bacteria, fungi, protozoa and viruses. Anaerobic
bacteria are highly associated with brain abscess, and is
rare involved in bacterial meningitis.
Central nervous system infectionswith anaerobic bacteria
are frequently curable owing to early detection and appro-
priate management. Taking medical histories (which is
helpful for estimating causative microorganisms), under-
standing of host factors (presence/absence of trauma and
operative history, the presence/absence of regional infection,
the immunological state, etc.) and physical ﬁndings provide
hints to early detection. Examination using computed
tomography (CT) andmagnetic resonance imaging (MRI) of
the brain are useful for making a deﬁnitive diagnosis.
Classiﬁcations of grade and evidence level
To indicate the criteria for scientiﬁc evidence for making
recommendations, the extents of treatment recommendations
were classiﬁed into A, B and C, and the evidence level was
also described with this classiﬁcation system (Table 1) [1].
The incidences of central nervous system infections
(particularly, brain abscess, subdural abscess, and epidural
abscess) are lower than those of other infections, and
approaches to organs of the central nervous system are
difﬁcult. For these reasons, there have been no or only a
few studies on central nervous system infections employing
systematic review, meta-analysis and randomized con-
trolled study. The number of clinical research on drug
transition is also limited. Therefore, the evidence for
antimicrobial therapy of central nervous system infections,
particularly infections in which anaerobes are involved, is
based on cohort studies and case series, which include
relatively small numbers of patients.
Brain abscess
Pathogenesis
Brain abscess is usually occurs by direct or secondary to
hematogenous dissemination from cerebral infection. The
diseases showing the former pattern of infection include
osteomyelitis, mastoiditis, chronic otitis media and
sinusitis, and abscesses of the frontal and temporal lobes
are characteristic. The diseases showing the latter
infection pattern include bacterial endocarditis, infectious
thrombophlebitis, congenital heart diseases with right
and left shunt, and drug abuse using intravenous (i.v.)
injection.
After infection occurs, inﬂammation progresses to a
necrotic state, and forms encapsulation. For several days to
several weeks thereafter, the intracranial pressure may be
increased by edema surrounding the abscess.
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Clinical features
Symptoms of elevated intracranial pressure, which include
headache, nausea/vomiting, seizures and personality
change, usually appear and progress. Focal neurological
ﬁndings and papilledema are also present.
Examination using CT and MRI of the brain are useful
for making the diagnosis. The presence/absence of lesions
including the auris media (middle ear) and the paranasal
sinuses can also be simultaneously observed. A typical
contrast CT image shows ring-enhancement of the capsule.
Brain abscess is regarded as a general contraindication
for lumbar puncture, because it may cause brain herniation.
Unless ventricular rupture of the abscess is present, cere-
brospinal ﬂuid ﬁndings are not helpful in making the
diagnosis. The rate of bacterial isolates is also lower than
10%, and even though rupture can occur, the rate is only
approximately 20%.
Puncture and drainage are frequently conducted under
CT or MRI guidance. The puncture ﬂuid collected during
drainage is subjected to culture of aerobes, anaerobes, acid-
fast bacteria and fungi. In some cases, there is no choice
but to start treating without identiﬁcation of the causative
bacteria because surgical treatment might not be feasible
depending on the patient’s condition.
Causative bacteria
Most microorganisms isolated from an abscess are usually
anaerobic bacteria (anaerobic gram-positive cocci, Prevotella
spp., Fusobacterium spp., etc.). A plurality of anaerobic
bacteria or polymicrobial infections with microaerophilic
Streptococci (Streptococcus milleri group) and aerobic
bacteria (Streptococci, Staphylococcus aureus, etc.) are the
causative bacteria of these infections [2].
It is important to isolate and identify causative bacteria
for appropriate therapeutic strategies. Causative organisms
are isolated from the materials aspirated or excised by
surgical treatment, and from blood culture. It takes a long
time for anaerobic bacteria to be isolated and identiﬁed. In
some cases, the bacteria involved may not to be isolated.
Under these circumstances, gram-stain ﬁndings of speci-
mens are useful for presumption of the causative bacteria.
Enteric bacteria and Pseudomonas aeruginosa are sus-
pected of being involved in brain abscess derived from
chronic otitis media. S. aureus is often isolated in case of
brain abscess that develops after brain injury, post-neuro-
surgery, or after the onset of endocarditis. Many cases have
positive blood cultures.
Antimicrobial therapy
Usually, empiric therapy targeting Streptococci and anaer-
obic bacteria, which frequently become causative bacteria,
is started.
In Western countries the combination use of PCG and
metronidazole is the standard empiric therapy. Streptococci
and anaerobic bacteria show good sensitivity to PCG,
which shows good penetration into the abscess cavity [3].
Metronidazole has been considered an important drug for
treating brain abscesses [4] [A-II], but this for i.v. injection
is not available in Japan. Since metronidazole shows high
bioavailability, it may be orally administered after the
primary i.v treatment [5]. Since the sensitivity of Strepto-
cocci [B-III] to metronidazole is low, this drug is always
used in combination with an antimicrobial agent effective
against Streptococci. Clindamycin (CLDM) with antibac-
terial activity against anaerobic bacteria is usually not used
in empiric therapy because it shows a poor penetration to
the central nervous system.
The drugs are listed in Tables 2 and 3 [6], taking into
consideration causative bacteria, the antibacterial drugs
available in Japan, and penetration of drugs to the central
nervous system and abscess cavity. Even though these
drugs are used at the maximum dose, which are approved
for medical use under the health insurance scheme in
Table 1 Classiﬁcations of grade and evidence level in this report
Classiﬁcation of grade level
A Implementation is highly recommended
B Implementation is recommended (on the basis of evidence)
C Implementation may be considered according to circumstances
Classiﬁcation of evidence level
I Evidence from one or more randomized controlled trials
II Evidence from non-randomized controlled trials, analytical epidemiological studies (cohort or case–control studies), descriptive studies
(case reports or case series)
III Evidence from opinions of expert committees or respected authorities, not based on patient data
Grade is classiﬁed by comprehensively taking into consideration the evidence level, variation in the number of pieces of evidence, clinical
efﬁcacy, ﬂexibility, and evidence pertaining to side-effects and costs (modiﬁed from Ref. [1])
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Japan, it must be difﬁcult to treat brain abscesses. We thus
have no choice but to administer these drugs at doses
higher than the approved maximum.
The drugs that should be used as ﬁrst-choice drugs in
Japan are sulbactam/ampicillin (SBT/ABPC) and tazobac-
tam/piperacillin (TAZ/PIPC). Since they have a b-lactamase
inhibiting action, they exert antibacterial activity against
Streptococci, methicillin-resistant S. aureus (MRSA),
anaerobic bacteria (including b-lactamase producing bacteria)
and gram-negative bacteria. The drug concentrations in the
abscess ﬂuid may not be constant, but the clinical effects
have been shown [7] [B-II].
Carbapenems are expected as alternative antimicrobial
agents for brain abscess, because these drugs show a good
penetration to the central nervous system and have excel-
lent antibacterial activity against Streptococci and anaero-
bic bacteria. The clinical efﬁcacy of imipenem/cilastatin
(IPM/CS) for brain abscess has been shown [8] [B-II], but
Table 2 Antimicrobial therapy for brain abscess involving anaerobic bacteria
Causative bacteria First-line drugs Second-line drugs
Anaerobic bacteria ± Streptococci (Bacteroides
fragilis, Fusobacterium species, Prevotella
species, Streptococcus milleri group,
Streptococci)
Sulbactam/ampicillin at a dose of 3–4.5 g
every 6 h ± cefotaxime at a dose of 2 g
every 6 h (ceftriaxone at a dose of 2 g every
12 h)a
Benzylpenicillin at a dose of 4,000,000 U
every 4 h + metronidazole at a dose of
500 mg 4 times a day (oral administration)
Anaerobic bacteria + enteric bacteria Sulbactam/ampicillin at a dose of 3–4.5 g
every 6 h + cefotaxime at a dose of 2 g every
6 h (ceftriaxone at a dose of 2 g every 12 h)
Metronidazole at a dose of 500 mg 4 times a
day (oral administration) + cefotaxime or
meropenem at a dose of 2 g every 8 h
Anaerobic bacteria + Staphylococcus aureus Sulbactam/ampicillin at a dose of 3–4.5 g
every 6 h + vancomycin at a dose of 1 g
every 12 hb
Metronidazole at a dose of 500 mg 4 times a
day (oral administration) or meropenem at
a dose of 2 g every 8 h + vancomycinb
Anaerobic bacteria + Pseudomonas aeruginosa Sulbactam/ampicillin at a dose of 3–4.5 g
every 6 h + ceftazidime at a dose of 2 g
every 8 h (cefepime at a dose of 2 g every
12 h)
Metronidazole at a dose of 500 mg 4 times a
day (oral administration) + ceftazidime
(cefepime)
a When infection caused by Streptococci is suspected
b Single use of b-lactams may be used if it has a good antibacterial activity against S. aureus
Table 3 Empirical antimicrobial therapy for bacterial brain abscess (modiﬁed from Ref. [6])
Predisposing condition Highly probable causative bacteria Antimicrobial regimen (i.v. injections)a
Otitis media, mastoiditis Streptococci (aerobic, anaerobic), Bacteroides spp.,
Prevotella spp., enteric bacteria
Sulbactam/ampicillin at a dose of 3–4.5 g every
6 h + cefotaxime at a dose of 2 g every 6 h (or ceftriaxone at a




Streptococci (aerobic, anaerobic), Bacteroides spp.,
enteric bacteria, Staphylococcus aureus,
Haemophilus spp.
Sulbactam/ampicillin at a dose of 3–4.5 g every
6 h + cefotaxime at a dose of 2 g every 6 h (or ceftriaxone at a
dose of 2 g every 12 h) + vancomycin at a dose of 1 g every
12 h
Dental infections Mixed infections (Streptococci, Fusobacterium
spp., Prevotella spp., Bacteroides spp.)
Sulbactam/ampicillin at a dose of 3–4.5 g every 6 h
Traumatic, post-
neurosurgical
S. aureus, Streptococci, enteric bacteria,
Clostridium spp.
Vancomycin at a dose of 1 g every 12 h + cefotaxime at a dose
of 2 g every 6 h (or ceftriaxone at a dose of 2 g every 12 h)
Congenital heart
diseases




Fusobacterium spp., Actinomyces spp., Prevotella
spp., Streptococci, Nocardia spp.
Sulbactam/ampicillin at a dose of 3–4.5 g every
6 h + cefotaxime at a dose of 2 g every 6 h (or ceftriaxone at a
dose of 2 g every 12 h) (+sulfamethoxazole-trimetoprimc)
Bacterial endocarditis S. aureus, Streptococci Vancomycin at a dose of 1 g every 12 h + gentamicin 1 mg/kg
every 8 h
a Patient with normal renal and hepatic function
b If infection caused by Pseudomonas aeruginosa is suspected: ceftazidime at a dose of 2 g every 8 h (or cefepime at a dose of 2 g every 8–12 h)
c If infection caused by Nocardia species is suspected
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it is associated with an increased risk of seizures at a high
dose. There has been only a case report discussing treat-
ment with meropenem (MEPM), but it is listed here as a
secondary drug [B-III], since its pharmacokinetics and
pharmacological effects are mostly equivalent to those of
IPM/CS and a lower risk of convulsion.
Fluoroquinolones show an excellent penetration to the
central nervous system and good antibacterial activity
against gram-negative bacteria and P. aeruginosa. On the
basis of these properties, these agents are expected as an
alternative in cases that b-lactams are not applicable [C-II].
However, the use of these ﬂuoroquinolones has been
described in case reports only. It is therefore necessary to
examine the effectiveness of these agents for brain abscess.
The ﬂuoroquinolones for i.v. injection currently available
in Japan is inappropriate for empiric therapy because they
show poor antibacterial activity against Streptococci and
anaerobic bacteria.
When involvement of the penicillin-resistant Strepto-
cocci and enteric bacteria is suspected, the third-generation
cephalosporins [cefotaxime (CTX) and ceftriaxone (CTRX)]
with a good penetration to the central nervous system are
used [9, 10] [A-II]. Ceftazidime (CAZ) is used in the
treatment of brain abscesses derived from chronic otitis
media, because enteric bacteria and Pseudomonas aeru-
ginosa are often involved [11].
When the involvement of S. aureus in brain abscess is
suspected, vancomycin (VCM) is also used with antimi-
crobial agents [A-II]. The ﬁrst-generation cephems
[cefazolin (CEZ), etc.] are not appropriate for treating a
brain abscess, because they show poor penetration to the
central nervous system. Since penicillins for S. aureus
(nafcillin and oxacillin) are not available in Japan, we have
no choice but to use VCM to treat brain abscesses due to
S. aureus.
After the causative bacteria and drug sensitivity have
been identiﬁed, an unnecessary drug is changed or with-
drawn, and treatment with drugs suitable for the causative
bacteria should be continued. Although the most clearly
appropriate treatment period has yet to be established, 6- to
8-week treatment with injection(s) is recommended if
appropriate surgical treatment with appropriate antimicro-
bial agents [12] [A-II]. Three to 4 weeks of antimicrobial
therapy may be adequate for patients who have a favorable
clinical course.
Oral antibiotic therapy often follows the i.v. antibiotics
for 2–3 months [12]. In such cases, the antimicrobial
agents (metronidazole, oral ﬂuoroquinolones, etc.) with
good activity to the causative bacteria and a good pene-
tration to the central nervous system [C-III] are adminis-
tered. However, it is extremely unlikely that the clinical
usefulness and necessity of these antimicrobial agents have
been adequately assessed. When disappearance and/or
remarkable regression of the abscess are recognized in
brain CT and MRI examination, the antibacterial treatment
could be ﬁnished.
Necessity of surgical treatment
Most patients with bacterial brain abscess require surgical
management for optimal therapy (drainage, excision of the
abscess). Although no distinct period of the antibacterial
treatment without surgical treatment has been established,
antibacterial treatment with injections is continued for




Subdural abscess, which results from pus accumulation
between the dura mater and the arachnoid, spreads from
sinusitis (particularly, inﬂammation of the frontal and
ethmoidal sinuses) or otitis media in 60–90% of adult
cases.
Causative bacteria
The causative bacteria are nearly the same as the species
causing brain abscesses, and polymicrobial infections are
common [2, 13].
Post-operative and post-traumatic infections are com-
monly caused by Staphylococci and aerobic gram-negative
bacilli.
In infantile cases with subdural abscess, it is usually
recognized as a complication of bacterial meningitis [14].
Clinical features
Headache, decreased consciousness and seizures progress
for several days, leading to coma. Nearly 100% of cases
decease of the infection is not treated.
Diagnosis procedures are either CT or MRI. Lumber
puncture is a general contraindication in subdural abscess,
because there is very little information obtained by the
examination and the possibility of causing a cerebral
hernia.
Blood and anaerobic cultures of collected surgical
specimens are used to make the diagnosis.
Treatment
Subdural abscess is a medical emergency, and it requires
surgical approach such as drainage.
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Antimicrobial treatment conforms to that of brain
abscess. When S. aureus is a suspected pathogen, VCM
should be used empirically until the susceptibility is dem-
onstrated. When infection is likely caused by gram-nega-
tive bacilli, empiric therapy with cefepime, CAZ, cefpirom
and MEPM is appropriate. When the causative bacteria are
identiﬁed, the treatment should be switched to drugs sus-
ceptible to the microorganisms. Parenteral antimicrobial
therapy should be continued 3–4 weeks [15] after surgical
drainage [B-II].
Treatment of the paranasal sinuses causing subdural




Epidural abscess refers to a localized collection of pus
between the dura mater and the cranial bone or the spinal
canal.
Cranial epidural abscess develops from sinusitis (par-
ticularly, of the frontal sinus), otitis media, papillitis, skull
trauma and osteomyelitis of the skull.
Spinal epidural abscess is usually occurs secondary to
hematogenous dissemination from distant sites (particularly,
furuncles, skin infections such as cellulitis, periodontitis,
etc.), or develops from adjacent sites (spondylomyelitis,
retroperitoneal abscess, etc.). Approximately one-third of
these cases are idiopathic.
Causative bacteria
The causative bacteria of cranial epidural abscess are
mostly the same as those producing brain abscesses, and
involvement of anaerobic bacteria is recognized in
approximately 40% of cases [2]. When acute frontal sinus
inﬂammation causes a cranial epidural abscess, S. aureus
as well as Streptococci and anaerobic bacteria are fre-
quently involved.
S. aureus is a causative organism of spinal epidural
abscess, followed by Escherichia coli, P. aeruginosa and
multiple anaerobic bacteria.
Clinical features
Cranial epidural abscess manifests with regional pain in the
nasal cavity and the ear, and headache, pyrexia and con-
sciousness disturbance appear in association with the nasal
and ear pain. Seizures and focal neurological signs may
develop. Unlike subdural abscess, it is rare for emergency
treatment to be needed.
Spinal epidural abscess manifests with severe backache
and focal vertebral pain, which radiates into the area
innervated by the same nerve root. Muscle strength dete-
riorates due to compression of the spine or the lumbar root.
Muscle weakness initially progresses for several hours to
several days, and the condition may suddenly deteriorate
into quadriplegia or paraplegia. Pyrexia is recognized in
approximately two-thirds of cases.
Brain CT and MRI are both useful for making the
diagnosis, and MRI is superior to CT.
Blood culture is essential for microbial diagnosis. Gram-
stain ﬁndings of the specimens from surgical drainage ﬂuid
are useful for presumption of causative bacteria.
Treatment
Surgical drainage of cranial epidural abscess prevents the
complication of subdural abscess.
Antimicrobial therapy is usually continued for 3–6 weeks
after surgical drainage [16] [A-II]. The empiric therapy
should conform to that for brain abscess. Longer treatment
for 6–8 weeks should be needed if osteomyelitis is present
[B-II].
The principles of management for spinal epidural
abscess are prompt surgical decompression and drainage.
Empirical antimicrobial therapy must include antistaphy-
lococcal agent (VCM should be used before determination
of susceptibility) plus coverage for aerobic gram-negative
bacilli (e.g. cefepime, CAZ, MEPM, etc.). When the
causative bacteria are identiﬁed, treatment should be
switched to the drug susceptible to these microorganisms.
The antimicrobial therapy should usually continued for
approximately 8 weeks [17] [A-II].
Meningitis
Causative bacteria
The frequency of involvement of anaerobic bacteria in the
meningitis is very low,\1% [2]. When anaerobic bacteria
are involved, the main causative bacteria include Fuso-
bacterium spp., Bacteroides fragilis, anaerobic gram-posi-
tive cocci and Clostridium spp.
Antimicrobial therapy
In Western countries, i.v. metronidazole is usually used for
treatment, while in Japan this is not available, as mentioned
above. CLDM, which is frequently used for treating
anaerobic infections, is inappropriate for meningitis,
because its cerebrospinal ﬂuid concentration does not
reach the level necessary for adequate treatment despite
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inﬂammation of the meninges being present [6]. Therefore,
we choice in this guideline penicillins (penicillins with
b-lactamase inhibitors) and carbapenems, which excellent
activity against anaerobic bacteria.
The number of patients with anaerobic meningitis is
very small, and the efﬁcacy of combined therapy with
corticosteroids remains unclear.
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